GRAFT POLYMER UK LS -001 Cash Flow Conversion Efficiency
GRAFT POLYMER UK LS -001 cash flow conversion efficiency. Based on the latest financial reports, GRAFT POLYMER UK LS -001 (J4I) has a cash flow conversion efficiency ratio of -0.048x as of November 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-149.00K ≈ $-174.20K USD) by net assets (€3.08 Million ≈ $3.61 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of GRAFT POLYMER UK LS -001 (2023–2026)
Cash flow conversion efficiency of GRAFT POLYMER UK LS -001 from 2023 to 2026. This chart illustrates how GRAFT POLYMER UK LS -001's cash flow conversion efficiency has evolved over time, based on yearly financial data. View J4I stock price and chart for real-time trading data and today's change.
GRAFT POLYMER UK LS -001 Cash Flow Conversion Ratio Explained
GRAFT POLYMER UK LS -001 cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
GRAFT POLYMER UK LS -001 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GRAFT POLYMER UK LS -001 ranked by their cash flow conversion efficiency. Also see market cap of GRAFT POLYMER UK LS -001 for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Visgeneer
TWO:4197
|
-0.062x |
|
iTonic Holdings Ltd.
NASDAQ:ITOC
|
-0.050x |
|
Cerberus Cyber Sentinel Corp
NASDAQ:CISO
|
-0.006x |
|
Ascelia Pharma AB (publ)
ST:ACE
|
-0.137x |
|
Cohort
LSE:CHRT
|
0.229x |
|
Millennium Silver Corp
V:MSC
|
0.019x |
|
Lite Access Technologies Inc
V:LTE
|
1.235x |
|
Biomerica Inc
NASDAQ:BMRA
|
-0.347x |
Annual Cash Flow Conversion Efficiency for GRAFT POLYMER UK LS -001 (2023–2026)
The table below shows the annual cash flow conversion efficiency of GRAFT POLYMER UK LS -001 from 2023 to 2026. Review J4I free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-05-31 | €6.19 Million ≈ $7.24 Million |
€-3.27 Million ≈ $-3.83 Million |
-0.529x | -44.28% |
| 2025-05-31 | €3.08 Million ≈ $3.61 Million |
€-1.13 Million ≈ $-1.32 Million |
-0.366x | +40.04% |
| 2024-05-31 | €2.03 Million ≈ $2.37 Million |
€-1.24 Million ≈ $-1.45 Million |
-0.611x | -17.91% |
| 2023-05-31 | €4.55 Million ≈ $5.32 Million |
€-2.36 Million ≈ $-2.76 Million |
-0.518x | -- |
About GRAFT POLYMER UK LS -001
Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre… Read more